NCT00170755View on ClinicalTrials.gov

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

718

Participants

Timeline

Start Date

April 30, 2002

Study Completion Date

January 31, 2005

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

Darifenacin

Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily

Trial Locations (1)

07936-108

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00170755 - A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder | Biotech Hunter | Biotech Hunter